Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycemic and inflammatory status in type 2 diabetes after antiviral therapy for hepatitis C
PACTR201712002777310Not yet recruiting
- Start
- Nov 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sofosbuvir, daclatasvir, simeprevir, ribavirin, metformin and 1 more in hepatitis C virus infection and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by none. Planned start Nov 2017; status: not yet recruiting.
02
Drugs
sofosbuvirdaclatasvirsimeprevirribavirinmetformin
03
Conditions
hepatitis C virus infectiontype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on PACTR201712002777310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201712002777310.